BRIEF published on 10/20/2026 at 07:05, 21 days 13 hours ago Innate Pharma Announces Conference Call on its Portfolio and Finances Conference Call Financial Situation Innate Pharma Immunothérapies Marseille
BRIEF published on 10/20/2026 at 07:05, 21 days 13 hours ago Innate Pharma Annonce une Conférence Téléphonique sur son Portefeuille et ses Finances Conférence Téléphonique Innate Pharma Immunothérapies Marseille Sitution Financière
PRESS RELEASE published on 10/20/2026 at 07:00, 21 days 13 hours ago Informations privilégiées / Autres communiqués Innate Pharma organise une conférence téléphonique pour présenter l'avancée de son portefeuille et sa situation financière du troisième trimestre 2026 Conférence Téléphonique Portefeuille Situation Financière Innate Pharma Avancée
PRESS RELEASE published on 09/17/2026 at 07:00, 1 month 23 days ago Informations privilégiées / Autres communiqués
PRESS RELEASE published on 09/17/2026 at 07:00, 1 month 23 days ago Inside Information / Other news releases
BRIEF published on 09/16/2026 at 22:05, 1 month 23 days ago Innate Pharma and Sobi Partnership Becomes Effective Innate Pharma Lacutamab Sobi Partnership TELLOMAK-3 Study T-cell Lymphoma
BRIEF published on 09/16/2026 at 22:05, 1 month 23 days ago Le partenariat entre Innate Pharma et Sobi entre en vigueur Innate Pharma Lacutamab Partenariat Sobi Étude TELLOMAK-3 Lymphome À Cellules T
BRIEF published on 09/16/2026 at 22:05, 1 month 23 days ago Innate Pharma et Sobi officialisent leur partenariat Partenariat Stratégique Innate Pharma Phase 3 TELLOMAK-3 Sobi Lymphomes T
BRIEF published on 09/16/2026 at 22:05, 1 month 23 days ago Innate Pharma and Sobi formalize their partnership Strategic Partnership Innate Pharma Phase 3 TELLOMAK-3 Sobi T-cell Lymphomas
PRESS RELEASE published on 09/16/2026 at 22:00, 1 month 23 days ago Inside Information / Other news releases Innate Pharma and Sobi partnership becomes effective after meeting closing conditions, triggering USD 75 million payment and commencing TELLOMAK-3 Phase 3 study in Q1 2027 Partnership Innate Pharma Closing Conditions Sobi TELLOMAK-3
Published on 11/10/2026 at 14:45, 6 hours 6 minutes ago An Investigational Drug to Tackle Measles Outbreaks
Published on 11/10/2026 at 14:31, 6 hours 20 minutes ago First Breach Plans to Integrate Onboard AI Computing into CQS and LRS Drone Platforms
Published on 11/10/2026 at 14:30, 6 hours 21 minutes ago Stabilis Solutions Announces Three-Year Take-Or-Pay LNG Supply Agreement with Existing Aerospace Customer
Published on 11/10/2026 at 14:30, 6 hours 21 minutes ago ACCESS Newswire Reports Third Quarter 2026 Results
Published on 11/10/2026 at 14:00, 6 hours 51 minutes ago Horizon Aircraft Completes Preliminary Design Review of Cavorite X7 Hybrid eVTOL
Published on 11/10/2026 at 19:21, 1 hour 30 minutes ago ALTHEORA, Mäder Composites France et IPC s'associent pour donner une seconde vie aux matériaux composites
Published on 11/10/2026 at 18:54, 1 hour 56 minutes ago REPLOID Group AG pursues entry in the US market and secures exclusivity to conduct due diligence for the potential acquisition of Chapul, LLC.
Published on 11/10/2026 at 18:45, 2 hours 6 minutes ago Special Optics Introduces Purpose-Built Microscope Objectives for Quantum Applications
Published on 11/10/2026 at 18:30, 2 hours 21 minutes ago Shelly Group Accelerates Revenue Growth in the Third Quarter and Confirms Full-Year 2026 Guidance
Published on 11/10/2026 at 18:00, 2 hours 51 minutes ago Déclaration du nombre total des droits de vote et du nombre d’actions au 31 octobre 2026
Published on 11/10/2026 at 17:45, 3 hours 6 minutes ago Damartex / Descriptif du programme de rachat d'actions
Published on 11/10/2026 at 17:35, 3 hours 16 minutes ago ENGIE - Déclaration du nombre total d'actions et de droits de vote au 31 octobre 2026
Published on 11/10/2026 at 17:31, 3 hours 20 minutes ago CNP Assurances SA annonce le succès de l’émission d’une obligation subordonnée Tier 2 de 500 M€.
